[EN] EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF [FR] INHIBITEURS DE PROTÉINES DE LIAISON À L'EMOPAMIL ET LEURS UTILISATIONS
摘要:
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
The invention relates to novel compounds having the general formula I, and which compounds are useful to manufacture a medicament to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma, and vasoconstriction, e.g. hypertension.
[EN] EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PROTÉINES DE LIAISON À L'EMOPAMIL (EBP) ET LEURS UTILISATIONS
申请人:BIOGEN MA INC
公开号:WO2023154499A1
公开(公告)日:2023-08-17
Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
Synthesis of novel tetrahydroisoquinoline bronchodilators
作者:Maria F. Dalence-Guzmán、Jörgen Toftered、Viveca Thornqvist Oltner、David Wensbo、Martin H. Johansson
DOI:10.1016/j.bmcl.2010.07.057
日期:2010.9
The synthesis and bronchorelaxing effects of a series of novel tetrahydroisoquinoline amides are described. The compounds were evaluated for their ability to relax LTD4 contracted isolated human small airways ex-vivo. Several compounds demonstrated highly efficacious bronchorelaxing properties. Cinnamide 71 was selected for further studies and constitutes a promising candidate as a novel bronchorelaxing agent for the treatment of pulmonary disorders. (C) 2010 Elsevier Ltd. All rights reserved.
[EN] EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PROTÉINES DE LIAISON À L'EMOPAMIL ET LEURS UTILISATIONS
申请人:[en]BIOGEN MA INC.
公开号:WO2024020156A1
公开(公告)日:2024-01-25
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.